BlackRock Fund Advisors’s Atara Biotherapeutics ATRA Stock Holding History

BlackRock Fund Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$15.8M	Buy	44,460 +5,417	+14%	+$2.29M	﹤0.01%	2312
2016 Q3	$20.9M	Buy	39,043 +2,486	+7%	+$1.35M	﹤0.01%	2047
2016 Q2	$20.6M	Buy	36,557 +5,730	+19%	+$2.75M	﹤0.01%	2011
2016 Q1	$14.7M	Buy	30,827 +883	+3%	+$397K	﹤0.01%	2153
2015 Q4	$19.8M	Buy	29,944 +13,874	+86%	+$10.5M	﹤0.01%	2048
2015 Q3	$12.6M	Buy	16,070 +2,222	+16%	+$2.71M	﹤0.01%	2266
2015 Q2	$18.3M	Buy	13,848 +6,099	+79%	+$7M	﹤0.01%	2170
2015 Q1	$8.05M	Buy	7,749 +1,432	+23%	+$946K	﹤0.01%	2570
2014 Q4	$4.22M	Buy	+6,317	New	+$3.86M	﹤0.01%	2965

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Fund Advisors's ATRA Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Atara Biotherapeutics (ATRA) stake by 14% in Q4 2016, buying an estimated $2.29M and bringing the position to 44,460 shares worth $15.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2312.

BlackRock Fund Advisors first reported a position in ATRA in Q4 2014 and has held it in 9 quarters since. The position peaked at $20.9M in Q3 2016. 85 funds tracked by Wall St. Rank hold ATRA as of Q4 2016.

BlackRock Fund Advisors held 44,460 shares of Atara Biotherapeutics worth $15.8M as of Q4 2016.
BlackRock Fund Advisors bought 5,417 Atara Biotherapeutics shares in Q4 2016, an estimated $2.29M.
Atara Biotherapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2312 holding.
BlackRock Fund Advisors first reported a position in Atara Biotherapeutics in Q4 2014 and has held it in 9 quarters since.
BlackRock Fund Advisors's Atara Biotherapeutics position peaked at $20.9M in Q3 2016.
85 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.